http://orcid.org/0000-0002-9970-7051
References
- Takahashi H, Nasu K, Minami M, et al. Organ atrophy induced by sorafenib and sunitinib - quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen. Pol J Radiol. 2016;81:557–565.
- Phillip V, Zahel T, Bärtl K, et al. Influence of sorafenib and bevacizumab on pancreatic volume - a monocentric CT based analysis. Pancreatology. 2016;16(4):621–624.
- Nakamura M, Yamada Y, Muro K, et al. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Future Oncol. 2015;11(10):1471–1478.
- de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947.
- Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–237.
- Sullivan S. Pancreatic atrophy from sorafenib. N Engl J Med. 2014;370(2):186.
- Hescot S, Vignaux O, Goldwasser F. Pancreatic atrophy-a new late toxic effect of sorafenib. N Engl J Med. 2013;369(15):1475–1476.
- Ganten MK, Schuessler M, Bruckner T, et al. Pancreatic atrophy in hepatocellular carcinoma patients receiving long-term treatment with sorafenib. Oncology. 2015;89(2):88–94.
- Shinohara N, Takahashi M, Kamishima T, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104(2):241–247.
- Hatano T, Ishii G, Endo K, et al. Shrinkage of prostate volume in sunitinib-treated patients with renal cell carcinoma. Jpn J Clin Oncol. 2013;43(12):1282–1285.
- Takahashi H, Masuoka S, Nasu K, et al. Sorafenib-induced prostate volume reduction, a new adverse effect detected by imaging: a pilot study. J Belg Soc Radiol. 2018;102(1):69.
- Shinagare AB, Steele E, Braschi-Amirfarzan M, et al. Sunitinib-associated Pancreatic atrophy in patients with gastrointestinal stromal tumor: a toxicity with prognostic implications detected at imaging. Radiology. 2016;281(1):140–149.
- Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28(6):1054–1060.
- Mir O, Coriat R, Boudou-Rouquette P, et al. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol. 2012;23(1):280–281.